Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.

Madlen JentzschJuliane GrimmMarius BillDominic BrauerDonata BackhausRosmarie PointnerKaroline GoldmannJulia SchulzDietger NiederwieserUwe PlatzbeckerSebastian Schwind

Published in: American journal of hematology (2021)

Keyphrases

stem cell transplantation
patients undergoing
high dose
acute myeloid leukemia
low dose
allogeneic hematopoietic stem cell transplantation
bone marrow